Clarke, ex rel v. Mikhail

779 S.E.2d 150, 243 N.C. App. 677, 2015 N.C. App. LEXIS 905
CourtCourt of Appeals of North Carolina
DecidedNovember 3, 2015
Docket15-235
StatusPublished
Cited by12 cases

This text of 779 S.E.2d 150 (Clarke, ex rel v. Mikhail) is published on Counsel Stack Legal Research, covering Court of Appeals of North Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Clarke, ex rel v. Mikhail, 779 S.E.2d 150, 243 N.C. App. 677, 2015 N.C. App. LEXIS 905 (N.C. Ct. App. 2015).

Opinion

TYSON, Judge.

*678 Timothy Clarke ("Plaintiff"), personal representative of the Estate of Erica Bohn, appeals from judgment entered by the trial court after a jury returned a verdict in favor of Ashraf Gad Bakhom Mikhail, M.D., Jessica Lyn Hardin, P.A., and Coastal Carolina Neuropsychiatric Center, P.A. (collectively, "Defendants"). Plaintiff also appeals from order denying his motion for a new trial. We find no prejudicial error.

I. Factual Background

Plaintiff commenced this wrongful death and medical malpractice action against Dr. Ashraf Gad Bakhom Mikhail ("Dr. Mikhail"), Jessica Hardin ("Ms. Hardin"), and Coastal Carolina Neuropsychiatric Center *679 ("CCNC") on 30 September 2011. Plaintiff alleged Ms. Hardin was negligent in prescribing and dosing a drug, Lamictal, to treat Erica Bohn's ("Ms. Bohn's") severe mental illness. Plaintiff filed an amended complaint seeking punitive damages on 3 December 2013.

A. Erica Bohn's Medical History and Treatment

Ms. Bohn first sought treatment at CCNC, an outpatient psychiatric practice located in Jacksonville, North Carolina, on 26 February 2009. CCNC was the only clinic located in Onslow County with a full-time psychiatric practice in 2009. Prior to receiving treatment at CCNC, Ms. Bohn had been involuntarily committed five times by other healthcare providers between 2006 and 2008. A magistrate and two medical providers all determined Ms. Bohn demonstrated a desire to *154 harm herself or others for each involuntary commitment.

Ms. Bohn was seen and evaluated by Dr. Mikhail, a psychiatrist and owner of CCNC. Ms. Bohn reported a history of diagnosis and treatment for paranoid schizophrenia to Dr. Mikhail. She also reported feelings of sadness, fear, and poor concentration. Dr. Mikhail noted Ms. Bohn displayed depressive symptoms of generalized sadness and poor concentration, and anxiety symptoms of excessive worries, restlessness, muscle tension, specific anxiety, and panic attacks. Dr. Mikhail diagnosed Ms. Bohn with paranoid schizophrenia and generalized anxiety disorder.

Ms. Bohn reported numerous stressors in her life, which affected or resulted from her mental illness. She had been married and divorced twice. Her second husband was abusive. She lost custody of her only son, Eddie, after she held a knife to him and the Department of Social Services ("DSS") intervened.

Eddie also suffered from severe mental illness, and had been involuntarily committed and admitted to residential mental health programs numerous times beginning at nine years old. Ms. Bohn lived with and cared for her aging and ill parents.

Ms. Bohn possessed an increased risk of suicide attributed to her diagnosis, depressive symptoms, lack of financial resources, lack of friends, and lack of family support. She posed an even higher risk of suicide due to her prior history of hospitalizations.

Ms. Hardin, a physician's assistant under Dr. Mikhail's supervision at CCNC, was primarily responsible for Ms. Bohn's direct treatment thereafter. Ms. Bohn engaged in therapy and medication management at CCNC. She admitted past "suicidal ideations" in her therapy sessions *680 at CCNC. Ms. Bohn had failed all typical and atypical antipsychotic medications her previous two psychiatrists had prescribed. Ms. Hardin's treatment objective was to manage Ms. Bohn's fluctuating symptoms, to help keep her out of the hospital, and to prevent her from hurting herself or others.

In April 2010, Ms. Hardin prescribed Lithium as a mood stabilizer for Ms. Bohn's depression and anxiety. Ms. Bohn reported "she was having increased moments that she wanted to cry and felt very sad since having started the [L]ithium" at her 25 May 2010 appointment with Ms. Hardin. Ms. Hardin testified Ms. Bohn initially responded well to the Lithium, but certain medications intended to decrease depression can increase depressive symptoms instead.

Ms. Hardin was aware of Ms. Bohn's chronic mental illness, history of hospitalizations, lack of family support, lack of friends, multiple stressors in her life, and her general increased risk of suicide. Ms. Hardin's goal was to maintain Ms. Bohn's stability and function, and noted Ms. Bohn was "going downhill" at her 25 May 2010 appointment.

Ms. Hardin prescribed Lamictal to Ms. Bohn at this appointment. Ms. Hardin testified she based her decision, in part, on the fact that Ms. Bohn "was sad ... [and] was already on or had been on antidepressants, which at times were effective and at times were not effective[,]" and "ha[d] initially responded well to the [L]ithium[.]" Ms Hardin explained "Lamictal is chemically similar to [L]ithium, but has a more favorable side effect profile [.]" Ms. Hardin also testified she

was aware of the literature that supports Lamictal as augmentation for depression and the literature that supports it in regards to its mood-stabilizing properties, and [Ms. Bohn] repeatedly throughout her chart was kind of speckled with that sadness, or the ups and downs or irritability, so I thought the Lamictal was appropriate for her.

Lamictal is a prescription drug and carries a "black box" warning, mandated by the United States Food and Drug Administration ("FDA"). The "black box" warning states Lamictal carries the risk of a severe rash, known as Stevens-Johnson Syndrome ("SJS"), in 0.8 out of every 1,000 adult patients. SJS causes blistering of the skin. The outer layer of a patient's skin, the epidermis, dies and separates from the lower layer, the dermis. SJS causes this rash to *155 occur on less than ten percent of a patient's body.

SJS's rash can develop into toxic epidermal necrolysis ("TEN") if left untreated, which affects at least thirty percent of a patient's skin.

*681 The skin is the body's largest organ and plays a major role in the body's immune functions. Patients with TEN are at an increased risk for infection, due to the skin not being intact. A patient can die from complications arising from TEN. Large amounts of fluids, electrolytes, and proteins are lost through the open wounds, which further compromises the body's ability to fight infection because of this malnutrition.

The "black box" warning advises that the risk of developing SJS increases if the drug's titration, or dosing schedule, differs from the titration recommended in the package insert. The manufacturer's suggested titration of Lamictal is: 25 milligrams daily for the first two weeks, 50 milligrams daily for weeks three and four, 100 milligrams daily for week five, and 200 milligrams daily for week six and thereafter.

The record from Ms. Bohn's 25 May 2010 CCNC appointment showed Ms. Hardin instructed Ms. Bohn to take 25 milligrams of Lamictal daily for the first week, and increase the dosage to 50 milligrams daily in the second week. Ms.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Moore v. Richmen Enters., LLC
Court of Appeals of North Carolina, 2026
Shakespeare v. Novant Healthcare Inc.
W.D. North Carolina, 2023
WALLS v. FORD MOTOR COMPANY
M.D. North Carolina, 2022
Hill v. Boone
Court of Appeals of North Carolina, 2021
Monroe v. Rex Hosp.
Court of Appeals of North Carolina, 2020
Hampton v. Hearn
Court of Appeals of North Carolina, 2020
Erik Phillips v. Pneumo Abex, LLC
713 F. App'x 191 (Fourth Circuit, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
779 S.E.2d 150, 243 N.C. App. 677, 2015 N.C. App. LEXIS 905, Counsel Stack Legal Research, https://law.counselstack.com/opinion/clarke-ex-rel-v-mikhail-ncctapp-2015.